Latest filing published 26 Jan 2026 for Coherus Oncology, Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Dennis M. Lanfear, listed as chief executive, appears in our data through filings on Coherus Oncology, Inc. shares, published by SEC (Form 4). We count 13 filings; the first trade dates from 6 June 2021 and the latest from 23 January 2026.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
The latest filing, published on 26 January 2026, reports a share grant in Coherus Oncology, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
13 of 13 declarations